GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 501–600 of 880
BAJAJ, H. S., Aljabri, B. A., & Verma, S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000562 · Cited by 14
The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies
Cheung, P., & Eriksson, O. (2021) · Biomedicines · doi:10.3390/biomedicines9121824 · Cited by 13
Karabulut, S., Coşkun, Z. M., & Bolkent, S. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.01.010 · Cited by 16
Incretin-based therapy: renal effects
Korbut, A. I., & Klimontov, V. V. (2016) · Diabetes Mellitus · doi:10.14341/dm7727 · Cited by 16
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Incretin receptor agonism during pregnancy: implications for mother and baby
Dearden, L., & Ozanne, S. E. (2025) · Clinical Science · doi:10.1042/cs20258493 · Cited by 15
“In adults, GLP1RAs increase mean heart rate via directly stimulating the sinoatrial node and enhancing sympathetic tone [26].”
Detection of a Parkinson's Disease–Specific MicroRNA Signature in Nasal and Oral Swabs
Schließer, P., Struebing, F. L., Northoff, B. H., Kurz, A., Rémi, J., Holdt, L. M., Höglinger, G. U., Herms, J. W., & Koeglsperger, T. (2023) · Movement Disorders · doi:10.1002/mds.29515 · Cited by 17
“Interestingly, GLP1R mRNA expression is significantly increased in the substantia nigra of PD cases,(43) and GLP1R is also highly expressed in the myenteric plexus throughout the gut.(44) NCAPG2, which plays a role in chromosome assembly and segregation in mitosis, was found to be differentially expressed in a transcr…”
BackgroundThe protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 15
“GLP-1Rs are distributed widely throughout the body in humans and model organisms, with particular density in the pancreas β-cells, gastrointestinal tract, brain, kidneys, heart, and blood vessels of other organs [17, 18].”
BackgroundQuast, D. R., Xie, C. H., Bound, M. J., Grivell, J., Hatzinikolas, S., Jones, K. L., Horowitz, M., Rayner, C. K., Nauck, M. A., Meier, J. J., et al. (2025) · Diabetes · doi:10.2337/db24-0830 · Cited by 16
Mayer, A.-L., Scheitacker, I., Ebert, N., Klein, T., Amann, K., & Daniel, C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15320 · Cited by 15
“One key substrate of DPP-4 is, for example, GLP-1, but linagliptin effects on crescent formation mediated by the incretin GLP-1 are unlikely since in humans neither podocytes nor parietal epithelial cells express the GLP-1 receptor on their surface (Pyke et al., 2014).”
BackgroundIncretins and bone: friend or foe?
Mabilleau, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.007 · Cited by 14
“in 2013 [61 ], a growing body of evidence suggests that most of commercially available antibodies used in immunohistochemistry and western blotting in published studies are not specific of the GLP-1r [62 ,63].”
BackgroundSherman, S. I., Kloos, R. T., Tuttle, R. M., Pontecorvi, A., Völzke, H., Harper, K. D., Vance, C., Alston, J. T., Usborne, A. L., Sloop, K. W., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13437 · Cited by 15
Morieri, M. L., Targher, G., Lapolla, A., D'Ambrosio, M., Tadiotto, F., Rigato, M., Frison, V., Paccagnella, A., Simioni, N., Avogaro, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.049 · Cited by 15
Usborne, A. L., Byrd, R. A., Meehan, J., Blackbourne, J. L., Sullivan, J., Poitout‐Belissent, F., Préfontaine, A., Martin, J. A., & Vahle, J. L. (2015) · Toxicologic Pathology · doi:10.1177/0192623315596857 · Cited by 12
“In humans and macaques, the GLP-1 receptor is predominately present in the b-cells and also to a lesser extent in acinar cells, however, it is unclear if the receptor is expressed in acinar cells in rats (Gier et al. 2012; Xu et al. 1999; Zhou et al. 1999; Wild et al. 2006; Gotthardt et al. 2002; Pyke et al. 2014).”
BackgroundGLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“Conversely, GLP-1R was not found in primate liver tissue with no direct evaluation of human liver tissue GLP-1R distribution [83].”
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
“Thus, GLP-1R mRNA has been identified in several human tissues, including the pancreas, lung, kidney, hypothalamus, stomach, and heart, but not consistently in liver or adipose tissue [109].”
Metformin—mechanisms of its glycemia-reducing effect
Drewe, J., Foretz, M., & Krähenbühl, S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100106 · Cited by 19
Borah, A. K., Ahmed, S. A., & Borah, J. C. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100225 · Cited by 15
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
“In human hepatocytes, however, GLP‐1 receptor expression and activity are still controversial.(11,73)”
Non-invasive quantification of stem cell-derived islet graft size and composition
Lithovius, V., Lahdenpohja, S., Ibrahim, H., Saarimäki‐Vire, J., Uusitalo, L., Montaser, H., Mikkola, K., Yim, C., Keller, T., Rajander, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06194-5 · Cited by 13
“Many of these studies used tracers targeting the glucagon-like peptide 1 receptor (GLP1R), expressed in human pancreas primarily in beta cells [41, 42].”
BackgroundIncretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“In addition to pancreatic β-cells, GLP-1 receptors are also expressed in the kidney, lung, heart, walls of arteries, and gastrointestinal tract [14 ], indicating the potential role of GLP-1R agonists in the therapy of diabetic complications.”
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 14
“Mechanistic studies have shown that GLP-1 R is present in sinus node cells of the heart and induce intracellular calcium overload via cyclic adenosine monophosphate (cAMP)-dependent signaling pathways, which in turn causes an increase in heart rate [60, 61].”
GLP-1 for Treating Obesity—Origin, History, and Evolution
Knudsen, L. B. (2024) · JAMA · doi:10.1001/jama.2024.18000 · Cited by 11
Self-citationGlucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“In human hearts, GLP-1R mRNA was detected in all four chambers (Baggio et al. 2018), however, the detection of GLP-1R protein in the heart was less successful, with one excep-tion—a clear expression of GLP-1R observed in the sinoatrial node (Pyke et al. 2014).”
Fuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Pasta, A., Facciorusso, A., Torres, M. C. P., Giannini, E. G., & Sacco, R. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70000 · Cited by 16
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut–bone axis
Longo, M., Mathiesen, D. S., Gasbjerg, L. S., Esposito, K., Lund, A., & Knop, F. K. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0231 · Cited by 15
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
“They can also: (i) improve the composition of gut microbiota; (ii) suppress he-patic de novo lipogenesis; (iii) decrease enterocyte chylomicron production/secretion and (iv) promote β -oxidation of NEFAs inside the hepatocytes [79, 81, 82, 86].”
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Kameda, R., Cho, K. Y., Nomoto, H., Nakamura, A., Omori, K., Nagai, S., Sachiko, E., Kawata, S., Takeuchi, J., Kameda, H., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109069 · Cited by 14
Thomson, S. C., & Vallon, V. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0991-7 · Cited by 12
Osonoi, T., Saito, M., Osonoi, Y., Douguchi, S., Ofuchi, K., & Katoh, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0070 · Cited by 13
“21,22 Increased heart rate could be associated with a higher risk of all-cause mortality and cardiovascular events.”
Espinoza, L., Fedorchak, S., & Boychuk, C. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.624595 · Cited by 11
Eshghi, S. R. T., Fletcher, K., Myette‐Côté, É., Durrer, C. G., Gabr, R. Q., Little, J. P., Senior, P. A., Steinback, C. D., Davenport, M. H., Bell, G. J., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00154 · Cited by 13
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Hepprich, M., Antwi, K., Waser, B., Reubi, J. C., Wild, D., & Christ, E. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/4510910 · Cited by 13
Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Katsiki, N., Christou, G. A., & Kiortsis, D. N. (2015) · Current Vascular Pharmacology · doi:10.2174/157016111401151126161741 · Cited by 12
Decreased expression of the GLP-1 receptor after segmental artery injury in mice
Bjørnholm, K. D., Povlsen, G. K., Ougaard, M. E., Pyke, C., Rakipovski, G., Tveden-Nyborg, P., Lykkesfeldt, J., & Skovsted, G. F. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0608 · Cited by 10
Self-citationGEORGAKOPOULOU, V. E., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100449 · Cited by 10
“The GLP-1 receptor is expressed in human airway smooth muscle cells, pulmonary vascular smooth muscle, and eosinophils, providing a clear anatomical basis for direct pulmonary action [27,28].”
Wang, X.-Y., Liu, Y., Cao, L.-X., Li, Y.-Z., Wan, P., & Qiu, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-34070-6 · Cited by 12
Huang, X., Wu, M., Lin, J., Mou, L., Zhang, Y., & Jiang, J. (2024) · Medicine · doi:10.1097/md.0000000000038236 · Cited by 11
“[46,47] Consequently, under the intricate and extensive regulatory effects, patients are highly prone to GIAEs.”
BackgroundGad, H., Mohammed, I., Dauleh, H., Pasha, M., Al-Barazenji, T., Hussain, K., & Malik, R. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1385463 · Cited by 11
Hu, Q., Zhang, L., Tao, Y., Xie, S., Wang, A., Luo, C., Yang, R., Shen, Z., He, B. H., Fang, Y., et al. (2024) · Pharmacology · doi:10.1159/000540654 · Cited by 19
“Notably, hepatocytes do not express GLP-1R [20].”
Karakasis, P., Patoulias, D., Giannakoulas, G. A., Sagris, Μ., Theofilis, P., Fragakis, N., & Biondi‐Zoccai, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216411 · Cited by 13
“GLP-1R is widely expressed beyond the pancreas, including in various organs and tissues throughout the body, reflecting its broad physiological roles that extend beyond glucose regulation [16,17].”
BackgroundTran, D. T., Yeung, E. S. H., Hong, L. Y. Q., Kaur, H., Advani, S. L., Liu, Y., Syeda, M. Z., Batchu, S. N., & Advani, A. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01525-3 · Cited by 13
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
“[29] have shown using a new specific monoclonal”
BackgroundMethodLi, A. P. Z., & Kariyawasam, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00098-0 · Cited by 11
In vitro cell cultures of Brunner’s glands from male mouse to study GLP-1 receptor function
Voetmann, L. M., Underwood, C. R., Rolin, B., Hansen, A. K., Kirk, R. K., Pyke, C., Knudsen, L. B., & Frederiksen, K. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00345.2021 · Cited by 10
Self-citationBell, D. S. H. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7787732 · Cited by 12
“While GLP-1 receptors have been demonstrated in the kidney, the receptors in humans are confined to the proximal tubule and preglomerular vascular smooth muscle cells [60].”
BackgroundSleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
Fang, J., Miller, P., & Grigson, P. S. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.012 · Cited by 13
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
“To date, GLP-1 receptor mRNA has been detected in different kidney vascular structures, proximal tubular cells, and resident and infiltrating inflammatory cells [46–49].”
BackgroundEvolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Koureta, E., & Cholongitas, Ε. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1343587 · Cited by 15
Eda, H., Fukui, H., Uchiyama, R., Kitayama, Y., Hara, K., Yang, M., Kodani, M., Tomita, T., Oshima, T., Watari, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177232 · Cited by 12
Palee, S., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Physiological Research · doi:10.33549/physiolres.933558 · Cited by 11
“GLP-1 receptor is expressed in the heart and ventricular myocyte and has a high affinity with a specific GLP-1 receptor agonist liraglutide (Pyke et al. 2014, Saraiva et al. 2014).”
BackgroundHashimoto Takigami, N., Kuniyoshi, S., Miki, Y., Tamaki, K., Kamada, Y., Uehara, K., Tsuchiya, S., Terukina, S., Iwabuchi, E., Kanai, A., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06288-3 · Cited by 10
The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
Nilsson, M. S. D., Bove, K. B., Suhrs, H. E., Hermann, T. S., Madsbad, S., Holst, J. J., Prescott, E., & Zander, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.01.004 · Cited by 10
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 12
“express the GLP-1 receptors [72], and the effect of liraglutide on non-alcoholic steatohepatitis may be secondary to weight”
BackgroundLiraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline
Yi, B., Su, K., Cai, Y., Chen, X., Bao, Y., & Wen, Z. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176905 · Cited by 12
Kim, Y. C., Das, V., Kanoo, S., Yao, H., Stanford, S. M., Bottini, N., Karihaloo, A. K., & Vallon, V. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00231.2024 · Cited by 9
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305641 · Cited by 10
Kitsunai, H., Shinozaki, Y., Furusawa, S., Kitao, N., Ito, M., Kurihara, H., Oba‐Yamamoto, C., Takeuchi, J., Nakamura, A., Takiyama, Y., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18010129 · Cited by 12
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 14
Si, J., Yu, K., Hao, J., Wang, J., & Zhang, L. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251332035 · Cited by 11
“…family, exhibits broad tissue distribution including the pancreas, gastrointestinal tract, heart, lungs, kidneys, lymphatic system, and CNS. 27,28 Activation of GLP-1R by its ligand mediates intracellular homeostasis maintenance and confers neuroprotection against oxidative stress,…”
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
“GLP-1R are also found in smooth muscle cells in the walls of arteries in kidneys and lungs, myocytes of the sinoatrial node of the heart, and Brunner ’ s glands of gastrointestinal tract (3).”
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
Guo, J. S., Hayes, M. R., Leggio, L., Oru, E., & Rinaman, L. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.1375-25.2025 · Cited by 13
Notomi, Y., Isomura, T., Kanai, S., Maeda, M., Hoshino, J., Kondo, T., Fukada, Y., & Furukawa, K. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.04.006 · Cited by 9
Vahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T. E., Pienkowski, T. P., Rosol, T. J., Snyder, P. W., & Klöppel, G. (2015) · Toxicologic Pathology · doi:10.1177/0192623315588999 · Cited by 11
“The potential for direct, receptor-mediated effects of dulaglutide on the ductal epithelium appears unlikely due to the lack of GLP-1 receptor expression in pancreatic duct epithelial cells using a well-characterized monoclonal antibody (Pyke et al. 2014).”
BackgroundGlucagon transiently stimulates mTORC1 by activation of an EPAC/Rap1 signaling axis
Sunilkumar, S., Kimball, S. R., & Dennis, M. D. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110010 · Cited by 10
van der Kroon, I., Joosten, L., Nock, B. A., Μάινα, Θ., Boerman, O. C., Brom, M., & Gotthardt, M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00495 · Cited by 9
Miglio, G., Vitarelli, G., Klein, T., & Benetti, E. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13739 · Cited by 10
“Notably, this finding confirms previous data which exclude a prominent action of incretin hormones on podocytes in mature glomeruli (Fujita et al., 2014; Pyke et al., 2014).”
ResultMarso, S. P., Hardy, E., Han, J., Wang, H., & CHILTON, R. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0370-z · Cited by 10
O'Brien, R., Buckley, M. M., Kelliher, A., & O’Malley, D. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13631 · Cited by 10
Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys
Liao, Y., Ma, A., Wang, Z., Zhou, Y., Liu, L., Zhang, N., Zhang, L., Prud’homme, G. J., & Wang, Q. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106218 · Cited by 9
Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health
Singh, K., Aulakh, S. K., Nijjar, G. S., Singh, S., Sandhu, A. P. S., Luthra, S., Tanvir, F., Kaur, Y., Singla, A., & Kaur, M. S. (2024) · Cureus · doi:10.7759/cureus.64738 · Cited by 20
“They are highly concentrated in the duodenum’s Brunner’s glands and found at lower levels in the stomach’s muscularis externa and the intestinal myenteric plexus neurons [27].”
BackgroundGharib, S. A., Vemireddy, R., Castillo, J., Fountaine, B. S., Bammler, T. K., MacDonald, J. W., Hull, R. L., & Zraika, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-76722-1 · Cited by 10
“Sections were then incubated in the following primary antisera: mouse monoclonal anti-GLP-1 (8G9; reacts with the amidated C-terminus of GLP-1(7–36)amide; Abcam, Cambridge, MA) or the extensively validated mouse monoclonal anti-GLP-1R clone 3F52 (Developmental Studies Hybridoma Bank, IA) 44,59 .”
BackgroundMethodPop, A. S. K., Dănilă, M. D., Giuchici, S., Buriman, D. G., Lolescu, B. M., Sturza, A., Muntean, D. M., & Lascu, A. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0384 · Cited by 11
Machida, A., Suzuki, K., Nakayama, T., Miyagi, S., Maekawa, Y., Murakami, R., Uematsu, M., Kitaoka, T., & Oishi, A. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.5.15 · Cited by 11
“17 19–21 GLP-1R is also expressed in the eyes, 22,23 particularly in ganglion cells and nerve fiber layers.”
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
“In general, despite that GLP-1 receptors are not present on hepatocytes [66], GLP-1 RAs can indirectly ameliorate hepatic biochemistry and histologic parameters.”
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 14
“Despite the lack of a specific glucagon-like peptide (GLP)-1 target in hepatocytes, GLP-1 agonists may have additional liver-specific benefits via improvement in insulin resistance, managing co-morbid T2DM, and improving lipotoxicity [242,243].”
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
On behalf of the TOPLEVEL investigators and study coordinators, Imazu, M., Nakano, A., Ito, S., Hamasaki, T., & Kitakaze, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06871-3 · Cited by 7
An, I. B., Byun, M. S., Yang, S. I., Choi, Y., Woo, J. W., Jang, H. C., & Sung, Y. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14058 · Cited by 7
Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy
Jøns, C., Porta‐Sánchez, A., Lai, P. F. H., Wauchop, M., Massé, S., Azam, M. A., Asta, J. A., Rose, R. A., & Nanthakumar, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119815 · Cited by 8
Li, X., Yu, X., Gao, Y. J., Zhao, W., Wang, Y., Yu, F., Fu, C., Gao, H., Cheng, M., & Li, B. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00769-x · Cited by 8
“GLP1R is expressed in different regions of lung tissue, such as tracheal submucosal glands, alveolar type II cells, and pulmonary artery smooth muscle [26].”
BackgroundCastiglione, R., Vivacqua, A., Santoro, M., Rose, D. D., Peluso, G., Panza, S., Aquila, S., & D’Agata, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113844 · Cited by 9
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
Guo, J., Zhang, X., Pan, R., Zheng, Y., Chen, W., & Wang, L. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2384897 · Cited by 11
“GLP-1R also significantly expressed in pancreas, lung, heart, and other organs [12].”
New Insights into Chronic Pancreatitis: Potential Mechanisms Related to Probiotics
Pan, Y., Li, J., Fan, Z., Chen, Y., Huang, X., & Wu, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091760 · Cited by 9
Riehl-Tonn, V. J., Medak, K. D., Rampersad, C., MacPhee, A., & Harrison, T. G. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241290317 · Cited by 12
“22 Nevertheless, there is reasonable agreement 23-25 that GLP-1R in the kidney is predominantly located in subsets of vascular smooth muscle cells, as shown in mice, monkeys, and humans.”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 10
Giblett, J. P., Clarke, S., Zhao, T. X., McCormick, L. M., Braganza, D. M., Densem, C. G., O'Sullivan, M., Adlam, D., Clarke, S., Steele, J., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.05.013 · Cited by 8
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Marre, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13975 · Cited by 11
Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 10
“GLP-1R is a G protein–coupled receptor widely distributed in the pancreas, lung, heart, kidney, vascular smooth muscle, fat cells, gastrointestinal tract, central nervous system, and other tissues [6].”
Squalene-PEG-Exendin as High-Affinity Constructs for Pancreatic Beta-Cells
Babič, A., Vinet, L., Chellakudam, V., Janikowska, K., Allémann, É., & Lange, N. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00186 · Cited by 9
Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamusPreprint
Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S. H., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557967 · Cited by 8
Self-citationRodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.